1. 799 Durable responses and immune activation with intratumoral electroporation of pIL-12 plus pembrolizumab in actively progressing anti-PD-1 refractory advanced melanoma: KEYNOTE 695 interim data. (10th December 2020) Authors: Fernandez-Penas, Pablo; Carlino, Matteo; Tsai, Katy; Atkinson, Victoria; Shaheen, Monaster; Thomas, Sajeve; Mihalcioiu, Catalin; Hagen, Tom Van; Roberts-Thomson, Rachel; Haydon, Andrew; Mant, Andrew; Butler, Marcus; Daniels, Gregory; Buchbinder, Elizabeth; Hyngstrom, John; Moller, Mecker; Puzanov... Journal: Journal for immunotherapy of cancer Issue: Volume 8(2020)Supplement 3 Page Start: A477 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. Human‐in‐the‐loop Control of a Humanoid Robot for Disaster Response: A Report from the DARPA Robotics Challenge Trials. Issue 2 (March 2015) Authors: DeDonato, Mathew; Dimitrov, Velin; Du, Ruixiang; Giovacchini, Ryan; Knoedler, Kevin; Long, Xianchao; Polido, Felipe; Gennert, Michael A.; Padır, Taşkın; Feng, Siyuan; Moriguchi, Hirotaka; Whitman, Eric; Xinjilefu, X.; Atkeson, Christopher G.; Iagnemma, Karl; Overholt, Jim Journal: Journal of field robotics Issue: Volume 32:Issue 2(2015) Page Start: 275 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. Optimization‐based Full Body Control for the DARPA Robotics Challenge. Issue 2 (5th January 2015) Authors: Feng, Siyuan; Whitman, Eric; Xinjilefu, X.; Atkeson, Christopher G.; Iagnemma, Karl; Overholt, Jim Journal: Journal of field robotics Issue: Volume 32:Issue 2(2015) Page Start: 293 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. P865 Safety & efficacy of lifileucel (LN-144) tumor infiltrating lymphocyte therapy in metastatic melanoma patients after progression on multiple therapies – independent review committee data update. (15th April 2020) Authors: Sarnaik, Amod; Khushalani, Nikhil; Chesney, Jason; Kluger, Harriet; Curti, Brendan; Lewis, Karl; Medina, Theresa; Thomas, Sajeve; Pavlick, Anna; Whitman, Eric; Algarra, Salvador; Corrie, Pippa; Hamid, Omid; Lutzky, Jose; Olah, Judit; Weber, Jeffrey; Larkin, James; Shi, Wen; DiTrapani, Kelly; Qin,... Journal: Journal for immunotherapy of cancer Issue: Volume 8(2020)Supplement 1 Page Start: A12 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
5. Phase IIIb safety results from an expanded-access protocol of talimogene laherparepvec for patients with unresected, stage IIIB–IVM1c melanoma. Issue 1 (February 2018) Authors: Chesney, Jason; Awasthi, Sanjay; Curti, Brendan; Hutchins, Laura; Linette, Gerald; Triozzi, Pierre; Tan, Marcus C.B.; Brown, Russell E.; Nemunaitis, John; Whitman, Eric; Windham, Christopher; Lutzky, Jose; Downey, Gerald F.; Batty, Nicolas; Amatruda, Thomas Journal: Melanoma research Issue: Volume 28:Issue 1(2018) Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
6. Systemic versus local responses in melanoma patients treated with talimogene laherparepvec from a multi-institutional phase II study. Issue 1 (15th March 2016) Authors: Kaufman, Howard L.; Amatruda, Thomas; Reid, Tony; Gonzalez, Rene; Glaspy, John; Whitman, Eric; Harrington, Kevin; Nemunaitis, John; Zloza, Andrew; Wolf, Michael; Senzer, Neil N. Journal: Journal for immunotherapy of cancer Issue: Volume 4:Issue 1(2016) Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
7. Systemic versus local responses in melanoma patients treated with talimogene laherparepvec from a multi-institutional phase II study. Issue 1 (December 2016) Authors: Kaufman, Howard; Amatruda, Thomas; Reid, Tony; Gonzalez, Rene; Glaspy, John; Whitman, Eric; Harrington, Kevin; Nemunaitis, John; Zloza, Andrew; Wolf, Michael; Senzer, Neil Journal: Journal for immunotherapy of cancer Issue: Volume 4:Issue 1(2016) Page Start: 1 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
8. Vemurafenib treatment for patients with locally advanced, unresectable stage IIIC or metastatic melanoma and activating exon 15 BRAF mutations other than V600E. Issue 6 (December 2017) Authors: Hallmeyer, Sigrun; Gonzalez, Rene; Lawson, David H.; Cranmer, Lee D.; Linette, Gerald P.; Puzanov, Igor; Taback, Bret; Cowey, C. Lance; Ribas, Antoni; Daniels, Gregory A.; Moore, Timothy; Gibney, Geoffrey T.; Tawbi, Hussein; Whitman, Eric; Lee, Geraldine; Mun, Yong; Liu, Shiyao; Hamid, Omid Journal: Melanoma research Issue: Volume 27:Issue 6(2017) Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗